Emerald Health Pharmaceuticals to Present at the Biotech Showcase™ Annual Conference

SAN DIEGO, Jan. 05, 2018 -- Emerald Health Pharmaceuticals Inc. (EHP), which is developing medications based on cannabinoid science, today announced that it will present at Biotech Showcase™ 2018 taking place on January 8-10 at the Hilton San Francisco Union Square.

Jim DeMesa, MD, CEO at Emerald Health Pharmaceuticals, will present at the Biotech Showcase™ as follows:

• Date: Monday, January 8, 2018
• Time: 9:15 AM PST
• Room: Franciscan - C (Ballroom Level)
• Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA

Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that Emerald Health will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”

About Emerald Health Pharmaceuticals Inc.

Emerald Health Pharmaceuticals is focused on developing its library of proprietary, synthetic cannabinoid-derivative drug candidates for the treatment of inflammatory and neurodegenerative diseases. The company has two families of new chemical entities, based on CBD and CBG, that it has modified through rational drug design to affect validated receptors pertinent to targeted diseases. Its first drug candidate, EHP-101, is focused on treating multiple sclerosis and scleroderma. Its second, EHP-102, is focused on treating Huntington’s disease and Parkinson’s disease. The company is advancing preclinical development with the intent to launch a Phase I clinical study in 2018. For more information, visit www.emeraldpharma.life. Emerald Health Pharmaceuticals is part of the Emerald Health group, which comprises multiple companies advancing diverse botanical, nutraceutical and pharmaceutical products that may provide wellness and medical benefits by interacting with the body’s important endocannabinoid system.

For more information: [email protected]

*  *  *

To the extent statements contained in this news release are not descriptions of historical facts regarding Emerald Health Pharmaceuticals Inc. they should be considered “forward-looking statements,” as described in the private securities litigation reform act of 1995, that reflect management’s current beliefs and expectations. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “hope,” “hypothesis,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “strategy,” “will,” “would,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes. Forward-looking statements contained in these presentations include, but are not limited to, statements regarding: (i) the success and timing of our product development activities and clinical trials; (ii) our ability to develop and commercialize our product candidates; (iii) our plans to research, discover, evaluate and develop additional potential product, technology and business candidates and opportunities; (iv) our and our partners’ ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process; (v) the size and growth potential of the markets for our product candidates, and our ability to serve those markets; (vi) the rate and degree of acceptance of our product candidates; (vii) our ability to attract and retain key scientific or management personnel; (viii) the anticipated timing of clinical data availability; (ix) our ability to meet our milestones; (x) our expectations regarding our ability to obtain and maintain intellectual property protection; (xi) the level of our corporate expenditures; (xii) the assessment of our technology by potential corporate partners; and (xiii) the impact of capital market conditions on us. Forward-looking statements are subject to known and unknown factors, risks and uncertainties that may cause actual results to differ materially from those expressed or implied by such forward looking statements. Undue reliance should not be placed on forward-looking statements. We undertake no obligation to update any forward-looking statements. Emerald Health Pharmaceuticals’ investigational drug products have not been approved or cleared by the FDA.